These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 32166967)
1. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Alvarez-Cardona JJ; Whited LK; Chemaly RF Future Microbiol; 2020 Apr; 15():389-400. PubMed ID: 32166967 [TBL] [Abstract][Full Text] [Related]
2. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Florescu DF; Keck MA Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1171-8. PubMed ID: 25120093 [TBL] [Abstract][Full Text] [Related]
4. The use of brincidofovir for the treatment of mixed dsDNA viral infection. Camargo JF; Morris MI; Abbo LM; Simkins J; Saneeymehri S; Alencar MC; Lekakis LJ; Komanduri KV J Clin Virol; 2016 Oct; 83():1-4. PubMed ID: 27513204 [TBL] [Abstract][Full Text] [Related]
5. Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant. Meena JP; Phillips RS; Kinsey S J Pediatr Hematol Oncol; 2019 Oct; 41(7):e467-e472. PubMed ID: 30969265 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Caruso Brown AE; Cohen MN; Tong S; Braverman RS; Rooney JF; Giller R; Levin MJ Antimicrob Agents Chemother; 2015 Jul; 59(7):3718-25. PubMed ID: 25733509 [TBL] [Abstract][Full Text] [Related]
7. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. Tippin TK; Morrison ME; Brundage TM; Momméja-Marin H Ther Drug Monit; 2016 Dec; 38(6):777-786. PubMed ID: 27851688 [TBL] [Abstract][Full Text] [Related]
8. Renal Toxicity in Pediatric Patients Receiving Cidofovir for the Treatment of Adenovirus Infection. Vora SB; Brothers AW; Englund JA J Pediatric Infect Dis Soc; 2017 Nov; 6(4):399-402. PubMed ID: 28419263 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease. Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients. Lee YJ; Neofytos D; Kim SJ; Cheteyan L; Huang YT; Papadopoulos EB; Jakubowski AA; Papanicolaou GA Transpl Infect Dis; 2018 Dec; 20(6):e12977. PubMed ID: 30120866 [TBL] [Abstract][Full Text] [Related]
11. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. Chittick G; Morrison M; Brundage T; Nichols WG Antiviral Res; 2017 Jul; 143():269-277. PubMed ID: 28093339 [TBL] [Abstract][Full Text] [Related]
12. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. Paolino K; Sande J; Perez E; Loechelt B; Jantausch B; Painter W; Anderson M; Tippin T; Lanier ER; Fry T; DeBiasi RL J Clin Virol; 2011 Feb; 50(2):167-70. PubMed ID: 21094081 [TBL] [Abstract][Full Text] [Related]
13. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. El-Haddad D; El Chaer F; Vanichanan J; Shah DP; Ariza-Heredia EJ; Mulanovich VE; Gulbis AM; Shpall EJ; Chemaly RF Antiviral Res; 2016 Oct; 134():58-62. PubMed ID: 27582067 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322 [TBL] [Abstract][Full Text] [Related]
15. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Muller WJ; Levin MJ; Shin YK; Robinson C; Quinones R; Malcolm J; Hild E; Gao D; Giller R Clin Infect Dis; 2005 Dec; 41(12):1812-6. PubMed ID: 16288409 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus infection in pediatric transplant recipients: are effective antiviral agents coming our way? Lopez SMC; Michaels MG; Green M Curr Opin Organ Transplant; 2018 Aug; 23(4):395-399. PubMed ID: 29846196 [TBL] [Abstract][Full Text] [Related]
18. New drug on the horizon for treating adenovirus. Wold WS; Toth K Expert Opin Pharmacother; 2015; 16(14):2095-9. PubMed ID: 26330121 [TBL] [Abstract][Full Text] [Related]
19. Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Tylden GD; Hirsch HH; Rinaldo CH Antimicrob Agents Chemother; 2015; 59(6):3306-16. PubMed ID: 25801568 [TBL] [Abstract][Full Text] [Related]